

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

| SUBMISSION TYPE: | NEW ASSIGNMENT | | | | | | | | | | | | | | | | |
|--|------------------------------|---------------|------------------------|---------------------|------------------------------|----------------------|------------|--------------------|----------------|-------------------|------------|---------------|------------|-------------------|------------|----------------------|------------|
| NATURE OF CONVEYANCE: | ASSIGNMENT | | | | | | | | | | | | | | | | |
| CONVEYING PARTY DATA | | | | | | | | | | | | | | | | | |
| <table border="1"><thead><tr><th>Name</th><th>Execution Date</th></tr></thead><tbody><tr><td>Adnan M.M. Mjalli</td><td>04/30/2009</td></tr><tr><td>Dharma Rao Polisetti</td><td>03/31/2009</td></tr><tr><td>Thomas Scott Yokum</td><td>03/26/2009</td></tr><tr><td>Kalpathy Santhosh</td><td>04/28/2009</td></tr><tr><td>Mustafa Guzel</td><td>03/26/2009</td></tr><tr><td>Christopher Behme</td><td>01/16/2009</td></tr><tr><td>Stephen Thomas Davis</td><td>04/15/2009</td></tr></tbody></table> | | Name | Execution Date | Adnan M.M. Mjalli | 04/30/2009 | Dharma Rao Polisetti | 03/31/2009 | Thomas Scott Yokum | 03/26/2009 | Kalpathy Santhosh | 04/28/2009 | Mustafa Guzel | 03/26/2009 | Christopher Behme | 01/16/2009 | Stephen Thomas Davis | 04/15/2009 |
| Name | Execution Date | | | | | | | | | | | | | | | | |
| Adnan M.M. Mjalli | 04/30/2009 | | | | | | | | | | | | | | | | |
| Dharma Rao Polisetti | 03/31/2009 | | | | | | | | | | | | | | | | |
| Thomas Scott Yokum | 03/26/2009 | | | | | | | | | | | | | | | | |
| Kalpathy Santhosh | 04/28/2009 | | | | | | | | | | | | | | | | |
| Mustafa Guzel | 03/26/2009 | | | | | | | | | | | | | | | | |
| Christopher Behme | 01/16/2009 | | | | | | | | | | | | | | | | |
| Stephen Thomas Davis | 04/15/2009 | | | | | | | | | | | | | | | | |
| RECEIVING PARTY DATA | | | | | | | | | | | | | | | | | |
| <table border="1"><tr><td>Name:</td><td>TransTech Pharma, Inc.</td></tr><tr><td>Street Address:</td><td>4170 Mendenhall Oaks Parkway</td></tr><tr><td>City:</td><td>High Point</td></tr><tr><td>State/Country:</td><td>NORTH CAROLINA</td></tr><tr><td>Postal Code:</td><td>27265</td></tr></table> | | Name: | TransTech Pharma, Inc. | Street Address: | 4170 Mendenhall Oaks Parkway | City: | High Point | State/Country: | NORTH CAROLINA | Postal Code: | 27265 | | | | | | |
| Name: | TransTech Pharma, Inc. | | | | | | | | | | | | | | | | |
| Street Address: | 4170 Mendenhall Oaks Parkway | | | | | | | | | | | | | | | | |
| City: | High Point | | | | | | | | | | | | | | | | |
| State/Country: | NORTH CAROLINA | | | | | | | | | | | | | | | | |
| Postal Code: | 27265 | | | | | | | | | | | | | | | | |
| PROPERTY NUMBERS Total: 1 | | | | | | | | | | | | | | | | | |
| <table border="1"><thead><tr><th>Property Type</th><th>Number</th></tr></thead><tbody><tr><td>Application Number:</td><td>12872580</td></tr></tbody></table> | | Property Type | Number | Application Number: | 12872580 | | | | | | | | | | | | |
| Property Type | Number | | | | | | | | | | | | | | | | |
| Application Number: | 12872580 | | | | | | | | | | | | | | | | |
| CORRESPONDENCE DATA | | | | | | | | | | | | | | | | | |
| Fax Number: (336)841-7020 <i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i> | | | | | | | | | | | | | | | | | |
| Phone: 336-841-0300 | | | | | | | | | | | | | | | | | |
| Email: rdailey@ttpharma.com | | | | | | | | | | | | | | | | | |
| Correspondent Name: Robert S. Dailey | | | | | | | | | | | | | | | | | |
| Address Line 1: 4170 Mendenhall Oaks Parkway | | | | | | | | | | | | | | | | | |
| Address Line 4: High Point, NORTH CAROLINA 27265 | | | | | | | | | | | | | | | | | |
| ATTORNEY DOCKET NUMBER: | 2008-03-US-D | | | | | | | | | | | | | | | | |

501279038

PATENT
REEL: 024923 FRAME: 0554

CH \$40.00 12872580

NAME OF SUBMITTER:

Robert S. Dailey

Total Attachments: 15

source=2008-03-US-D Assignment#page1.tif

source=2008-03-US-D Assignment#page2.tif

source=2008-03-US-D Assignment#page3.tif

source=2008-03-US-D Assignment#page4.tif

source=2008-03-US-D Assignment#page5.tif

source=2008-03-US-D Assignment#page6.tif

source=2008-03-US-D Assignment#page7.tif

source=2008-03-US-D Assignment#page8.tif

source=2008-03-US-D Assignment#page9.tif

source=2008-03-US-D Assignment#page10.tif

source=2008-03-US-D Assignment#page11.tif

source=2008-03-US-D Assignment#page12.tif

source=2008-03-US-D Assignment#page13.tif

source=2008-03-US-D Assignment#page14.tif

source=2008-03-US-D Assignment#page15.tif

PATENT

Title: Oxadiazanthracene Compounds For The Treatment Of Diabetes
Application Serial No.: 12/399,504
Attorney Docket No.: 2008-03-US

For: ☒ U.S. and/or ☒ Foreign Rights
For: ☒ U.S. Application or ☒ U.S. Patent
For: ☒ PCT Application

ASSIGNMENT OF INVENTION BY MULTIPLE INVENTORS

In consideration of the payment by ASSIGNEE to ASSIGNOR of the sum of One Dollar (\$1.00), the receipt of which is hereby acknowledged, and for other good and valuation consideration,

ASSIGNORS (Inventors):

Adnan M.M. Mjalli
Name of Inventor/Assignor

6421 Ashton Park Drive
Oak Ridge, North Carolina 27310
Address

United States
Nationality

Dharma Rao Polisetti
Name of Inventor/Assignor

3741 Deerfield Street
High Point, North Carolina 27265
Address

India
Nationality

Thomas Scott Yokum
Name of Inventor/Assignor

5108 Hartridge Way
Greensboro, NC 27407
Address

United States
Nationality

Kalpathy Santhosh
Name of Inventor/Assignor

4132 Tutbury Drive
Jamestown, North Carolina 27282
Address

India
Nationality

PATENT

Title: Oxadiazanthracene Compounds For The Treatment Of Diabetes

Application Serial No.: 12/399,504

Attorney Docket No.: 2008-03-US

Mustafa Guzel
Name of Inventor/Assignor

4058 Gunsmith Court
Jamestown, North Carolina 27282
Address

Turkey
Nationality

Christopher Behme
Name of Inventor/Assignor

3392 Cherrybrook Drive
Jamestown, NC 27282
Address

United States
Nationality

Stephen Thomas Davis
Name of Inventor/Assignor

1 Watroaks Court
Durham, NC 27703
Address

United States
Nationality

hereby sells, assigns, and transfers to

ASSIGNEE:

TransTech Pharma, Inc.

4170 Mendenhall Oaks Pkwy
High Point, North Carolina 27265
Address

A Delaware Corporation

and the successors, assigns and legal representatives of the ASSIGNEE the entire right, title, and interest for the United States and its territorial possessions and in all foreign countries, including all rights to claim priority in and to any all improvements which are disclosed in the invention entitled:

Oxadiazanthracene Compounds For The Treatment Of Diabetes

and which is found in U.S. Patent Application Serial No. 12/399,504, filed March 6, 2009, Attorney Docket Number 2008-03-US, and any legal equivalent thereof in a foreign country, including the right to claim priority and, in and to, Letters Patent to be obtained for said invention by the above application or any continuation, division, renewal, or substitute thereof, and as to letters patent any reissue or re-examination thereof;

PATENT

Title: Oxadiazanthracene Compounds For The Treatment Of Diabetes

Application Serial No.: 12/399,504

Attorney Docket No.: 2008-03-US

ASSIGNORS hereby covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment;

ASSIGNORS further covenant that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNORS and will testify as to the same in any interference, litigation, or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments, or affidavits required to apply for, obtain, maintain, issue, and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.


IN WITNESS WHEREOF, we have hereunto set our hands and seals,

SIGNATURES ARE ON FOLLOWING PAGES

PATENT

Title: Oxadiazanthracene Compounds For The Treatment Of Diabetes
Application Serial No.: 12/399,504
Attorney Docket No.: 2008-03-US

Adnan M.M. Mjalli
Name of Inventor


Signature of Inventor
4/30/09
Date

NOTARIZATION OR LEGALIZATION ACCOMPANYING ASSIGNMENT

NOTE: Executing this page is not required for assignment and is only prima facie evidence of execution. 35 USC 261.


Details of Country
and place of signing of assignment

Guilford County
North Carolina


Before me this 30th day of April, 2009, personally appeared the above named individual, **Adnan M.M. Mjalli**, to me known to be the person who is described in and who executed the foregoing assignment instrument and acknowledged to me that

☒ he ☐ she
executed the same of ☒ his ☐ her

own free will for the purpose therein expressed.


Notary Public or Consular Officer of the United
States of America

My commission expires 1-9-2010.



PATENT

Title: Oxadiazanthracene Compounds For The Treatment Of Diabetes
Application Serial No.: 12/399,504
Attorney Docket No.: 2008-03-US

Dharma Rao Polisetti
Name of Inventor -

P. Dharma Rao
Signature of Inventor

March 31, 2009
Date

NOTARIZATION OR LEGALIZATION ACCOMPANYING ASSIGNMENT

NOTE: Executing this page is not required for assignment and is only prima facie evidence of execution. 35 USC 261.

Details of Country
and place of signing of assignment

Guilford County
North Carolina


Before me this 31st day of March, 2009, personally appeared the above named individual, **Dharma Rao Polisetti**, to me known to be the person who is described in and who executed the foregoing assignment instrument and acknowledged to me that

☒ he ☐ she
executed the same of ☒ his ☐ her

own free will for the purpose therein expressed.

Kristin Nichol Neal
Notary Public or Consular Officer of the United
States of America

My commission expires January 9, 2010.



PATENT

Title: Oxadiazanthracene Compounds For The Treatment Of Diabetes

Application Serial No.: 12/399,504

Attorney Docket No.: 2008-03-US

Thomas Scott Yokum
Name of Inventor

TS Yokum
Signature of Inventor

3/26/09
Date

NOTARIZATION OR LEGALIZATION ACCOMPANYING ASSIGNMENT

NOTE: Executing this page is not required for assignment and is only prima facie evidence of execution. 35 USC 261.

Details of Country
and place of signing of assignment

Guilford County

North Carolina

Before me this 26th day of March, 2009, personally appeared the above named individual, **Thomas Scott Yokum**, to me known to be the person who is described in and who executed the foregoing assignment instrument and acknowledged to me that

☒ he

☐ she

executed the same of


☒ his

☐ her

own free will for the purpose therein expressed.

Kristin Nichol Neal
Notary Public or Consular Officer of the United
States of America

My commission expires January 9, 2010.




PATENT

Title: Oxadiazanthracene Compounds For The Treatment Of Diabetes

Application Serial No.: 12/399,504

Attorney Docket No.: 2008-03-US

Kalpathy Santhosh
Name of Inventor


Signature of Inventor

4/28/09
Date

NOTARIZATION OR LEGALIZATION ACCOMPANYING ASSIGNMENT

NOTE: Executing this page is not required for assignment and is only prima facie evidence of execution. 35 USC 261.

Details of Country
and place of signing of assignment

Guilford County
North Carolina


Before me this 28th day of April, 2009, personally appeared the above named individual, **Kalpathy Santhosh**, to me known to be the person who is described in and who executed the foregoing assignment instrument and acknowledged to me that

☒ he ☐ she
executed the same of ☒ his ☐ her

own free will for the purpose therein expressed.


Notary Public or Consular Officer of the United
States of America

My commission expires January 9, 2010.




PATENT

Title: Oxadiazanthracene Compounds For The Treatment Of Diabetes
Application Serial No.: 12/399,504
Attorney Docket No.: 2008-03-US

Mustafa Guzel
Name of Inventor

Signature of Inventor

Date


03/26/09

NOTARIZATION OR LEGALIZATION ACCOMPANYING ASSIGNMENT

NOTE: Executing this page is not required for assignment and is only prima facie evidence of execution. 35 USC 261.

Details of Country
and place of signing of assignment

Guilford County

North Carolina


Before me this 26th day of March, 2009, personally appeared the above named individual, **Mustafa Guzel**, to me known to be the person who is described in and who executed the foregoing assignment instrument and acknowledged to me that

☒ he ☐ she
executed the same of ☒ his ☐ her

own free will for the purpose therein expressed.


Notary Public or Consular Officer of the United
States of America

My commission expires January 9, 2010



PATENT

Title: Oxadiazanthracene Compounds For The Treatment Of Diabetes
Application Serial No.: 12/399,504
Attorney Docket No.: 2008-03-US

Christopher Behme
Name of Inventor

Signature of Inventor

Date

NOTARIZATION OR LEGALIZATION ACCOMPANYING ASSIGNMENT

NOTE: Executing this page is not required for assignment and is only prima facie evidence of execution. 35 USC 261.

Details of Country
and place of signing of assignment

Guilford County

North Carolina

Before me this _____ day of _____, 2009, personally appeared the above named individual, **Christopher Behme**, to me known to be the person who is described in and who executed the foregoing assignment instrument and acknowledged to me that

☒ he

☐ she

executed the same of ☒ his ☐ her

own free will for the purpose therein expressed.

Notary Public or Consular Officer of the United
States of America

My commission expires January 9, 2010.

PATENT

Title: Oxadiazanthracene Compounds For The Treatment Of Diabetes
Application Serial No.: 12/399,504
Attorney Docket No.: 2008-03-US

Stephen Thomas Davis
Name of Inventor

Stephen Davis
Signature of Inventor
4/15/2009
Date

NOTARIZATION OR LEGALIZATION ACCOMPANYING ASSIGNMENT

NOTE: Executing this page is not required for assignment and is only prima facie evidence of execution. 35 USC 261.

Details of Country
and place of signing of assignment

Guilford County
North Carolina


Before me this 15th day of April, 2009, personally appeared the above named individual, **Stephen Thomas Davis**, to me known to be the person who is described in and who executed the foregoing assignment instrument and acknowledged to me that

☒ he ☐ she
executed the same of ☒ his ☐ her

own free will for the purpose therein expressed.

Kristin Nichol Neal
Notary Public or Consular Officer of the United
States of America

My commission expires January 9, 2010.



AGREEMENT AND GENERAL RELEASE

TransTech Pharma, Inc. ("TransTech") and **Christopher Behme** Employee's heirs, executors, administrators, successors, and assigns (collectively referred to throughout this Agreement as "Employee"), agree that:

1. **Last Day of Employment.** Employee's last day of employment with TransTech is January 5, 2009.

2. **Consideration.** In consideration for signing this Agreement and General Release, and complying with its terms, TransTech agrees:

a. to pay to Employee [REDACTED]
[REDACTED] less lawful withholdings and deductions, which represents one month of salary at Employee's base rate of pay. This amount will be paid to Employee within fifteen (15) business days after TransTech's receipt of the original of this Agreement and General Release signed by Employee.

[REDACTED]

3. **No Consideration Absent Execution of this Agreement.** Employee understands and agrees that Employee would not receive the monies and/or benefits specified in paragraph "2" above, except for Employee's execution of this Agreement and General Release and the fulfillment of the promises contained herein.

[REDACTED]

[REDACTED]

keep

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

8. **Governing Law and Interpretation.** This Agreement and General Release shall be governed and conformed in accordance with the laws of North Carolina without regard to its conflict of laws provision. In the event of a breach of any provision of this Agreement and General Release, either party may institute an action specifically to enforce any term or terms of this Agreement and General Release and/or to seek any damages for breach. Should any provision of this Agreement and General Release be declared illegal or unenforceable by any court of competent jurisdiction and cannot be modified to be enforceable, excluding the general release language, such provision shall immediately become null and void, leaving the remainder of this Agreement and General Release in full force and effect.

[REDACTED]

10. **Amendment.** This Agreement and General Release may not be modified, altered or changed except in writing and signed by both Parties wherein specific reference is made to this Agreement and General Release.

11. **Entire Agreement.** This Agreement and General Release sets forth the entire agreement between the Parties hereto, and fully supersedes any prior agreements or understandings between the Parties, except the Employment Agreement which is incorporated herein by reference. Employee acknowledges that Employee has not relied on any representations, promises, or agreements of any kind made to Employee in connection with Employee's decision to accept this Agreement and General Release, except for those set forth in this Agreement and General Release.


[REDACTED]

EMPLOYEE MAY REVOKE THIS AGREEMENT AND GENERAL RELEASE FOR A PERIOD OF SEVEN (7) CALENDAR DAYS FOLLOWING THE DAY EMPLOYEE SIGNS THIS AGREEMENT AND GENERAL RELEASE. ANY REVOCATION WITHIN THIS PERIOD MUST BE SUBMITTED, IN WRITING, TO *NICOLE PEMBERTON* AND STATE, "I HEREBY REVOKE MY ACCEPTANCE OF OUR AGREEMENT AND GENERAL RELEASE." THE REVOCATION MUST BE PERSONALLY DELIVERED TO *NICOLE PEMBERTON* OR HER DESIGNEE, OR MAILED TO *NICOLE PEMBERTON* AND POSTMARKED WITHIN SEVEN (7) CALENDAR DAYS AFTER EMPLOYEE SIGNS THIS AGREEMENT AND GENERAL RELEASE.

EMPLOYEE AGREES THAT ANY MODIFICATIONS, MATERIAL OR OTHERWISE, MADE TO THIS AGREEMENT AND GENERAL RELEASE, DO NOT RESTART OR AFFECT IN ANY MANNER THE ORIGINAL UP TO FORTY-FIVE (45) CALENDAR DAY CONSIDERATION PERIOD.


EMPLOYEE FREELY AND KNOWINGLY, AND AFTER DUE CONSIDERATION, ENTERS INTO THIS AGREEMENT AND GENERAL RELEASE INTENDING TO WAIVE, SETTLE AND RELEASE ALL CLAIMS EMPLOYEE HAS OR MIGHT HAVE AGAINST RELEASEES AS OF THE DATE OF EXECUTION OF THIS AGREEMENT AND GENERAL RELEASE.

The Parties knowingly and voluntarily sign this Agreement and General Release as of the date(s) set forth below:

By: 
Christopher Behme

Date: 1/16/09

TRANSTECH PHARMA, INC.

By: 
Nicole Pemberton
Human Resources Manager

Date: 1/5/09